肌萎缩侧索硬化临床试验中药物遗传学交互作用的荟萃分析
该研究整合3项碳酸锂随机试验的个体数据,匹配UNC13A和C9orf72基因型,分析12个月生存率。总体碳酸锂未改善生存(HR 1.0, 95%CI 0.7-1.4; p=0.96)。UNC13A和C9orf72均为独立生存预测因子,碳酸锂对UNC13A携带者效果不同(p=0.027),其12个月生存概率从40.1%升至69.7%。
要点
- 碳酸锂总体未改善ALS患者12个月生存。
- UNC13A和C9orf72基因型是独立生存预测因子。
- 碳酸锂对UNC13A携带者可能有效,需前瞻验证。
核心结论
- 碳酸锂总体未改善ALS患者12个月生存,但UNC13A基因型可能影响疗效。
研究设计与样本
- 基于3项碳酸锂随机试验的个体参与者数据,匹配UNC13A和C9orf72基因型,518例参与者有临床数据。
主要发现
- 碳酸锂治疗12个月生存风险比HR 1.0(95%CI 0.7-1.4; p=0.96)。
- UNC13A基因型生存HR 2.4(95%CI 1.3-4.3; p=0.006)。
- C9orf72基因型生存HR 2.5(95%CI 1.1-5.2; p=0.032)。
- 碳酸锂对UNC13A携带者效果不同(p=0.027),对C9orf72携带者无差异(p=0.22)。
- UNC13A携带者12个月生存概率从40.1%(95%CI 23.2-69.1)提高到69.7%(95%CI 50.4-96.3)。
关键数值与推荐
- 12个月生存率为主要结局,总体HR 1.0(95%CI 0.7-1.4; p=0.96)。
- UNC13A携带者碳酸锂交互作用p=0.027,C9orf72交互作用p=0.22。
临床怎么用
- 提示未来ALS试验应聚焦基因型靶向治疗,并标准化基因分型以优化随机化和分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether genetic subgroups in recent amyotrophic lateral sclerosis (ALS) trials responded to treatment with lithium carbonate, but that the treatment effect was lost in a large cohort of nonresponders. METHODS: Individual participant data were obtained from 3 randomized trials investigating the efficacy of lithium carbonate. We matched clinical data with data regarding the UNC13A and C9orf72 genotype. Our primary outcome was survival at 12 months. On an exploratory basis, we assessed whether the effect of lithium depended on the genotype. RESULTS: Clinical data were available for 518 of the 606 participants. Overall, treatment with lithium carbonate did not improve 12-month survival (hazard ratio [HR] 1.0, 95% confidence interval [CI] 0.7-1.4; p = 0.96). Both the UNC13A and C9orf72 genotype were independent predictors of survival (HR 2.4, 95% CI 1.3-4.3; p = 0.006 and HR 2.5, 95% CI 1.1-5.2; p = 0.032, respectively). The effect of lithium was different for UNC13A carriers (p = 0.027), but not for C9orf72 carriers (p = 0.22). The 12-month survival probability for UNC13A carriers treated with lithium carbonate improved from 40.1% (95% CI 23.2-69.1) to 69.7% (95% CI 50.4-96.3). CONCLUSIONS: This study incorporated genetic data into past ALS trials to determine treatment effects in a genetic post hoc analysis. Our results suggest that we should reorient our strategies toward finding treatments for ALS, start focusing on genotype-targeted treatments, and standardize genotyping in order to optimize randomization and analysis for future clinical trials.
引用
- van Eijk RPA, Jones AR, Sproviero W, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017. PMID: 28978660. doi:10.1212/WNL.0000000000004606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。